✦ LIBER ✦

Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial

✍ Scribed by Norikazu Masuda; Yasuaki Sagara; Takayuki Kinoshita; Hiroji Iwata; Seigo Nakamura; Yasuhiro Yanagita; Reiki Nishimura; Hirotaka Iwase; Shunji Kamigaki; Hiroyuki Takei; Shinzaburo Noguchi

Book ID: 117785892
Publisher: The Lancet
Year: 2012
Tongue: English
Weight: 152 KB
Volume: 13
Category: Article
ISSN: 1470-2045
DOI: 10.1016/s1470-2045(11)70373-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Zoledronic acid prevents bone mineral de

Zoledronic acid prevents bone mineral density loss in premenopausal women receiving adjuvant treatment for hormone receptor-positive breast cancer: Preliminary results of a randomized, multicenter trial of zoledronic acid in patients receiving anastrozole or tamoxifen in combination with goserelin

✍ H. Hausmaninger 📂 Article 📅 2003 🏛 Elsevier Science 🌐 English ⚖ 184 KB

Preoperative gefitinib versus gefitinib

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

✍ Andreas Polychronis; H Dudley Sinnett; Dimitri Hadjiminas; Hemant Singhal; Janin 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 244 KB

Treatment Rationale Study Design for the

Treatment Rationale Study Design for the MetLung Trial: A Randomized, Double-Blind Phase III Study of Onartuzumab (MetMAb) in Combination With Erlotinib Versus Erlotinib Alone in Patients Who Have Received Standard Chemotherapy for Stage IIIB or IV Met-Positive Non–Small-Cell Lung Cancer

✍ David R. Spigel; Martin J. Edelman; Tony Mok; Kenneth O'Byrne; Luis Paz-Ares; We 📂 Article 📅 2012 🏛 CIG Media Group, LP. 🌐 English ⚖ 255 KB